Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
TREACE MEDICAL CONCEPTS, INC. (TMCI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/05/2023 |
4
| Elder Scot Michael (*See "Remarks") has filed a Form 4 on TREACE MEDICAL CONCEPTS, INC.|
Txns:
| Paid exercise price by delivering 402 shares
@ $0 |
|
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 06/08/2023 |
4
| BAYS F BARRY (Former Director) has filed a Form 4 on TREACE MEDICAL CONCEPTS, INC.|
Txns:
| Sold 48,503 shares
@ $26.51, valued at
$1.3M
Sold 1,042,318 shares
@ $26.51, valued at
$27.6M
|
|
| 06/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/01/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Forward Looking Statements and Other Cautions This",
"Treace Medical Concepts to Acquire Technology Enabling Patient Specific Instrumentation for Foot and Ankle Surgeries PONTE VEDRA, Fla. – June 1, 2023—Treace Medical Concepts, Inc. , a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus , today announced that it has signed an asset purchase agreement to acquire certain assets of MIOS Marketing, LLC d/b/a RedPoint Medical3D , a medical technology company offering pre-operative planning and patient-specific guides designed to deliver accurate surgical correction of deformities customized to the patient’s unique foot anatomy, for a purchase price of $20 million in an upfront cash payment, with up to $10 million in potential milestone payments. Using patient CT scan data, RPM-3D applies innovative s..." |
|
| 05/26/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/25/2023 |
4
| Hanna Betsy (Director) has filed a Form 4 on TREACE MEDICAL CONCEPTS, INC.|
Txns:
| Granted 2,753 shares
@ $0
Granted 6,305 options to buy
@ $26.34, valued at
$166.1k
|
|
| 05/25/2023 |
4
| MOTT RICHARD W (Director) has filed a Form 4 on TREACE MEDICAL CONCEPTS, INC.|
Txns:
| Granted 2,753 shares
@ $0
Granted 6,305 options to buy
@ $26.34, valued at
$166.1k
|
|
| 05/25/2023 |
4
| Berry Lance A (Director) has filed a Form 4 on TREACE MEDICAL CONCEPTS, INC.|
Txns:
| Granted 2,753 shares
@ $0
Granted 6,305 options to buy
@ $26.34, valued at
$166.1k
|
|
| 05/25/2023 |
4
| HAMILTON LAWRENCE W (Director) has filed a Form 4 on TREACE MEDICAL CONCEPTS, INC.|
Txns:
| Granted 2,753 shares
@ $0
Granted 6,305 options to buy
@ $26.34, valued at
$166.1k
|
|
| 05/25/2023 |
4
| Kiernan Jane E (Director) has filed a Form 4 on TREACE MEDICAL CONCEPTS, INC.|
Txns:
| Granted 2,753 shares
@ $0
Granted 6,305 options to buy
@ $26.34, valued at
$166.1k
|
|
| 05/25/2023 |
4
| BAKEWELL JOHN K (Director) has filed a Form 4 on TREACE MEDICAL CONCEPTS, INC.|
Txns:
| Granted 2,753 shares
@ $0
Granted 6,305 options to buy
@ $26.34, valued at
$166.1k
|
|
| 05/25/2023 |
4
| Jain Deepti (Director) has filed a Form 4 on TREACE MEDICAL CONCEPTS, INC.|
Txns:
| Granted 2,753 shares
@ $0
Granted 6,305 options to buy
@ $26.34, valued at
$166.1k
|
|
| 05/18/2023 |
4
| Scanlan Sean F. (Chief Innovation Officer) has filed a Form 4 on TREACE MEDICAL CONCEPTS, INC.|
Txns:
| Sold 25,000 shares
@ $25.4391, valued at
$636k
Exercised 25,000 options to buy
@ $0.1, valued at
$2.5k
|
|
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/08/2023 |
8-K
| Quarterly results|
Docs:
|
"Treace Medical Concepts Reports First Quarter 2023 Financial Results PONTE VEDRA, Fla. – May 8, 2023 — Treace Medical Concepts, Inc. , a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus , today reported financial results for the first quarter ended March 31, 2023. Recent Highlights: • Revenue of $42.2 million in the first quarter of 2023, a 45% increase over the same period last year. • Blended average revenue per Lapiplasty® procedure kit sold was $6,244, a 13% increase over the same period last year and a 6% increase sequentially. • Gross margin of 80.9% in the first quarter 2023. • First quarter revenue contribution from direct sales channel, the industry’s only direct bunion-focused salesforce, increased to 79..." |
|
| 05/02/2023 |
4
| TREACE JAMES T (Director) has filed a Form 4 on TREACE MEDICAL CONCEPTS, INC.|
Txns:
| Sold 40,000 shares
@ $25.0066, valued at
$1M
Sold 7,640 shares
@ $25.037, valued at
$191.3k
Sold 2,360 shares
@ $25.9103, valued at
$61.1k
|
|
| 05/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/28/2023 |
4
| BAYS F BARRY (Director) has filed a Form 4 on TREACE MEDICAL CONCEPTS, INC.|
Txns:
| Sold 16,204 shares
@ $25.55, valued at
$414k
Sold 11,600 shares
@ $25.3475, valued at
$294k
|
|
| 04/26/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/05/2023 |
4
| MOTT RICHARD W (Director) has filed a Form 4 on TREACE MEDICAL CONCEPTS, INC.|
Txns:
| Sold 201 shares
@ $26, valued at
$5.2k
Sold 15,756 shares
@ $26.0007, valued at
$409.7k
|
|
| 04/04/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/04/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/04/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/31/2023 |
4
| MOTT RICHARD W (Director) has filed a Form 4 on TREACE MEDICAL CONCEPTS, INC.|
Txns:
| Sold 38,498 shares
@ $26.0013, valued at
$1M
Sold 95,000 shares
@ $25.3582, valued at
$2.4M
|
|
| 03/31/2023 |
4
| TREACE JAMES T (Director) has filed a Form 4 on TREACE MEDICAL CONCEPTS, INC.|
Txns:
| Sold 50,000 shares
@ $25.8634, valued at
$1.3M
|
|
| 03/30/2023 |
4
| BAYS F BARRY (Director) has filed a Form 4 on TREACE MEDICAL CONCEPTS, INC.|
Txns:
| Sold 26,241 shares
@ $25.0238, valued at
$656.6k
Sold 32,457 shares
@ $25.2773, valued at
$820.4k
|
|
| 03/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/17/2023 |
4
| TIMBIE THOMAS E (Director) has filed a Form 4 on TREACE MEDICAL CONCEPTS, INC.|
Txns:
| Sold 50,000 shares
@ $23.0333, valued at
$1.2M
|
|
| 03/15/2023 |
4
| BAYS F BARRY (Director) has filed a Form 4 on TREACE MEDICAL CONCEPTS, INC.|
Txns:
| Sold 8,320 shares
@ $24.0731, valued at
$200.3k
Sold 1,080 shares
@ $24.7305, valued at
$26.7k
Sold 9,400 shares
@ $23.2482, valued at
$218.5k
|
|
| 03/10/2023 |
4
| Treace John T. (Chief Executive Offer) has filed a Form 4 on TREACE MEDICAL CONCEPTS, INC.|
Txns:
| Sold 2,075 shares
@ $24.41, valued at
$50.7k
Granted 82,475 shares
@ $0
Granted 186,900 options to buy
@ $24.07, valued at
$4.5M
|
|
|
|
|